Minnesota Law Review

Note, Immunity for Vaccine Manufacturers: The Vaccine Act and Preemption of Design Defect Claims

Vaccines are one of the most important medical advancements in history. Childhood immunization efforts are widely promoted by state and federal governments as well as medical professionals and institutions. While routine pediatric vaccines prevent many lethal and debilitating diseases, they also carry the potential to cause injury. Predictably, the occurrence of these injuries often leads to litigation against the vaccine manufacturers. The National Childhood Vaccine Injury Act of 1986 sought to address the issues of vaccine safety, compensation for vaccine-related injuries, and liability protection for vaccine manufacturers. The Act expressly preempts design defect claims for “unavoidable” side effects. Two courts have recently clashed in their interpretations of this language—the Georgia Supreme Court held that the language requires a case-by-case determination that the injury or side effect was unavoidable, while the Court of Appeals for the Third Circuit held that it preempts all design defect claims. After granting a writ of certiorari, the U.S. Supreme Court is now poised to determine the preemptive scope of the Vaccine Act.

The Note argues that the holdings of both courts are incorrect. While the Georgia Supreme Court correctly asserts that the Vaccine Act requires some case-by-case analysis, it fails to address who should undertake this analysis and whether it has already been performed with respect to routine childhood vaccines. Congress, and the institutions and agencies through which it operates, is the appropriate body for determining whether the benefits of particular vaccines justify their risks. In encouraging and, in some cases, mandating particular childhood vaccines, Congress has already made these determinations, rendering these vaccines “unavoidably unsafe” and shielding their manufactures from design defect claims. The federal government leads the way in national vaccine policy and must continue to do so to ensure the stability and supply of the vaccine market. Allowing such design defect claims could cripple the nation’s immunization programs and threaten the health and life of every American.

:: View PDF

News & Events

  • Volume 97 Lead Piece Profiled in New York Times

    The Volume 97 Lead Piece, a study of how the Supreme Court treats business interests by distinguished legal scholars Lee Epstein, William M. Landes, and Richard A. Posner, was profiled in the May 5, 2013 edition of the New York Times. The story, titled Corporations Find a Friend in the Supreme Court, [...]

  • Volume 98 Spring Submissions Closed

    The Minnesota Law Review has closed the spring submissions period for Volume 98. Submissions for Volume 98 will reopen on Thursday, August 1. Please see the submissions page for more details.

  • Volume 98 Submissions Will Open Feb. 15

    The Minnesota Law Review will begin accepting submissions for Volume 98 on Friday, February 15, 2013. Please see this page for more details.

  • Minnesota Law Review Announces Volume 98 Editorial Board

    The Minnesota Law Review is pleased to announce its Volume 98 editorial board, headed by Editor in Chief Jake Vandelist.

  • Minnesota Law Review Announces 2013 Symposium Topic

    The Minnesota Law Review is pleased to announce that its 2013 symposium will address the legal and political issues facing organized labor in the United States. The symposium will be held at the University of Minnesota Law School on October 25, 2013.

Newsletter

cforms contact form by delicious:days